Outcomes associated with serum phosphorus level in males with non-dialysis dependent chronic kidney disease

C P Kovesdy1, J E Anderson, K Kalantar-Zadeh

  • 1Division of Nephrology, Salem Veterans Affairs Medical Center, 1970 Roanoke Blvd., Salem, VA 24153, USA. csaba.kovesdy@va.gov

Clinical Nephrology
|April 1, 2010
PubMed

Insights

Elevated serum phosphorus levels in patients with chronic kidney disease (CKD) are linked to higher mortality. This study highlights the cumulative impact of high phosphorus on mortality risk in non-dialysis dependent CKD patients.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Public Health

Background:

  • Hyperphosphatemia is a known risk factor for mortality and end-stage renal disease (ESRD) in non-dialysis dependent chronic kidney disease (NDD-CKD).
  • Previous studies have not fully accounted for the cumulative effects of elevated serum phosphorus over time in NDD-CKD patients.

Purpose of the Study:

  • To investigate the association between cumulative serum phosphorus levels and mortality and kidney function decline in NDD-CKD.
  • To assess the impact of both baseline and time-averaged phosphorus levels on adverse outcomes.

Main Methods:

  • A cohort of 713 males with moderate to advanced NDD-CKD was analyzed.
  • Cox and mixed-effects models were used to examine associations between serum phosphorus (baseline and time-averaged) and outcomes.
  • Outcomes included all-cause mortality, a composite of mortality or ESRD, and the rate of estimated glomerular filtration rate (eGFR) decline.

Main Results:

  • Higher baseline and time-averaged serum phosphorus levels were significantly associated with increased mortality and the composite outcome.
  • A 1 mg/dl increase in time-averaged serum phosphorus correlated with a 1.56-fold increased hazard of all-cause mortality.
  • While unadjusted analyses showed an association between higher phosphorus and faster eGFR decline, this did not remain significant after multivariable adjustments.

Conclusions:

  • The cumulative burden of hyperphosphatemia is a significant predictor of mortality in patients with moderate and advanced NDD-CKD.
  • Further clinical trials are warranted to evaluate the efficacy of serum phosphorus reduction strategies on improving mortality in this patient population.
Abstract

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
Roles of Electrolytes: Calcium and Phosphate01:27

Roles of Electrolytes: Calcium and Phosphate

Calcium and phosphate are essential electrolytes in the human body, with calcium being the most abundant mineral. Around 99% of the body's calcium is stored in the skeleton and teeth, forming a crystal lattice of mineral salts in combination with phosphates. Calcium plays crucial roles in various bodily functions such as blood clotting, neurotransmitter release, muscle tone maintenance, and nervous and muscle tissue excitability.
The calcium concentration in blood plasma is primarily regulated...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...